(IN BRIEF) GSK and the University of Cambridge have announced a £50 million, five-year collaboration called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC) to accelerate research and development in kidney and respiratory diseases. The initiative combines GSK’s expertise in immunology and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AI, Cambridge University, Cambridge-GSK Translational Immunology Collaboration (CG-TIC), GSK, immunology, investment, Kidney and Respiratory Diseases, Nicolas Wisniacki, partnership, Peter Kyle, Professor David Thomas, safety, sustainability, Tony Wood
(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated a significant reduction in nasal polyp size and nasal obstruction after … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged chronic rhinosinusitis, Depemokimab, GSK, Kaivan Khavandi, Nasal Polyps, safety
(IN BRIEF) GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses against influenza A and B strains in both younger and older adults. The trial met success criteria … Read the full press release
Posted in Business, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged flu vaccine, GSK, mRNA, Phase II, Phase III, safety, Tony Wood
(IN BRIEF) GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and SWIFT-2 phase III trials. Administered every six months, it also demonstrated a 72% reduction in hospitalizations and emergency visits, offering … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged David Jackson, Depemokimab, GSK, Phase III Trials, safety, Severe Asthma Attacks, SWIFT-1, SWIFT-2
(IN BRIEF) GSK will present significant research at the 2024 European Respiratory Society (ERS) Congress, including data from phase III trials of its new biologic, depemokimab, for severe asthma. The presentations highlight GSK’s commitment to advancing respiratory medicine, with a … Read the full press release
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) GSK has announced encouraging findings from the interim analysis of the DREAMM-8 phase III trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex) compared to the standard of care, bortezomib plus PomDex, for relapsed or … Read the full press release
(IN BRIEF) GSK plc has announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, an oral antibiotic aimed at treating uncomplicated urogenital gonorrhoea in adolescents and adults. The trial demonstrated gepotidacin’s non-inferiority compared to the current … Read the full press release
(IN BRIEF) GSK plc has finalized the acquisition of Aiolos Bio, bolstering its respiratory biologics portfolio with AIO-001, a promising long-acting anti-TSLP monoclonal antibody for treating asthma. AIO-001, set to enter phase II clinical trials, targets severe asthma patients with … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Aiolos Bio, biologics, GSK, respiratory, Tony Wood
(IN BRIEF) GSK plc has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B (CHB). The Fast Track designation aims to expedite the development … Read the full press release
Posted in Business, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Bepirovirsen, Chronic Hepatitis B Treatment, FDA Fast Track, GSK
(IN BRIEF) GSK has received marketing authorization from the European Commission for Omjjara (momelotinib), an oral inhibitor targeting JAK1/JAK2 and activin A receptor type 1 (ACVR1). Omjjara is the first approved treatment in the EU for disease-related splenomegaly (enlarged spleen) … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Francesca Palandri, GSK, Myelofibrosis Treatment, Nina Mojas, Omjjara, splenomegaly
(IN BRIEF) GSK has submitted a regulatory application to the European Medicines Agency (EMA) to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. The … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adults Aged 50-59, COPD, GSK, NCT05590403, RSV Vaccination, vaccine
(IN BRIEF) GSK plc has announced positive results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial, evaluating the use of Jemperli (dostarlimab) in combination with standard chemotherapy and as maintenance therapy for patients with primary advanced or recurrent endometrial … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged chomotherapy, dostarlimab, Endometrial Cancer Trial, GSK, Hesham Abdullah, RUBY, Zejula
(IN BRIEF) In a significant development, GSK plc has received marketing authorization from the European Commission (EC) for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy as a treatment option for adult patients suffering from mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) … Read the full press release
(IN BRIEF) GlaxoSmithKline (GSK) has reported positive results from the interim efficacy analysis of the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial successfully met its primary endpoint of … Read the full press release
(IN BRIEF) GSK, a leading pharmaceutical company, has unveiled plans to conduct Phase III trials in 2024 for a low carbon version of its popular inhaler, Ventolin (salbutamol). The initiative aims to reduce greenhouse gas emissions associated with the inhaler’s … Read the full press release
Posted in Business, Environment, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged emissions, Emma Walmsley, GSK, health, Low Carbon Inhaler, respiratory conditions, sustainability, Ventolin
(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cabotegravir, CHINA, Chinese Approval, Deborah Waterhouse, GSK, HIV, injection, partnership, Pfizer, Rekambys, rilpivirine, Shionogi, sustainability, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) ViiV Healthcare, a global specialist HIV company, will present 23 abstracts at the 19th Annual European AIDS Conference (EACS 2023). These abstracts will cover various aspects of HIV treatment and prevention, including real-world data on long-acting and 2-drug … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Apretude, Dovato, EACS 2023, GSK, HIV, Kimberly Smith, partnership, Pfizer, prevention, Rekambys, Rukobia, Shionogi, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of Jemperli (dostarlimab) in combination with chemotherapy as a frontline treatment for adult … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged chemotherapy, CHMP, dostarlimab, endometrial cancer, GSK, Hesham Abdullah, Jemperli, RUBY, treatment
(IN BRIEF) Lloyds Banking Group has appointed Suresh Balaji as its Chief Marketing Officer, effective from October 16. In his new role, Balaji will oversee the Brand, Marketing, and Experience function for the group. He will be responsible for developing … Read the full press release
Posted in Banks, Business, Financial, Marketing, United Kingdom
Tagged appointment, GSK, leadership, Lloyds Banking Group, marketing, Standard Chartered Bank, Suresh Balaji, United Breweries, WPP
(IN BRIEF) GlaxoSmithKline (GSK) has announced a confidential settlement in the Cantlay/Harper case filed in California state court, which was scheduled for trial in November 2023. Additionally, GSK has settled the three remaining breast cancer bellwether cases in California, effectively … Read the full press release
Posted in Business, Government, Healthcare, Industrial, Law, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged breast cancer, California, Confidential Settlements, GSK, litigation, Zantac
(IN BRIEF) GSK plc has announced an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to co-promote GSK’s shingles vaccine, Shingrix, in China for an initial three-year period, with the potential for extension. Zhifei, China’s largest vaccine company by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged CHINA, GSK, Luke Miels, partnership, Shingles, Shingrix Vaccine, Zhifei
(IN BRIEF) GSK plc has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) to prevent respiratory syncytial virus (RSV) disease in adults aged 60 and above. This marks … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adults Aged 60 and Above, AReSVi-006, Arexvy, GSK, Japan, RSV Vaccine, Tony Wood, wellness
(IN BRIEF) Pharmaceutical company GSK and international non-profit organization Save the Children have renewed their partnership for another five years, with GSK committing £15 million to the initiative. The collaboration will primarily focus on increasing child vaccination rates and reducing … Read the full press release
Posted in Business, Government, Healthcare, Industrial, Management, News, Non Profit, Pharma & Biotech, Science, Security & Safety, Society, United Kingdom
Tagged Child Vaccination Rates, Dr Thomas Breuer, Dr. Lia Tadesse, ETHIOPIA, GSK, Nigeria, partnership, Save the Children, Xavier Joubert, Zero dose children
(IN BRIEF) A team led by current students and recent graduates has created Nestwork, a new platform that leverages peer-to-peer learning to help students find and secure their ideal careers. The platform simplifies career discovery through technology while supporting university … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Technology, United Kingdom
Tagged Amanda Berry, Career Discovery Platform, Flynn Duggan, Grant Thornton, GSK, investment, job, Loughborough Careers Network, Loughborough University, Nestwork, partnership, Peer-to-Peer, PoborEruesegbefe, Samsung, Samuel Ola, Sky, Som E-Agwuegbo
(IN BRIEF) Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas. This acquisition will reinforce Sandoz’s hospital … Read the full press release
(NOTICIA EN BREVE) Sandoz, líder mundial en medicamentos sin patente (genéricos y biosimilares), ha firmado un acuerdo para adquirir los derechos de producto a nivel mundial del agente antifúngico sistémico líder Mycamine® (micafungina sódica, Funguard® en Japón) de Astellas. Esta … Read the full press release
The Alliance for Clean Air, launched by the World Economic Forum and the Clean Air Fund, published a practical guide on how businesses can quantify the air pollutant emissions along their value chains The Alliance for Clean Air has adopted … Read the full press release
Posted in Business, Energy, Gas & Oil, Environment, Industrial, Management, Switzerland
Tagged air pollution, air pollution footprint, Andreas Ahrens, Claire Lund, Clean Air Fund, Climate and Clean Air Coalition, climate change conference, COP26, EY, GEA Group, GlaxoSmithKline, GSK, Haleon, Inter IKEA Group, Moderna, Oracle, Pim Valdre, Stockholm Environment Institute, sustainability, The Alliance for Clean Air, World Economic Forum
La Alianza para el Aire Limpio, lanzada por el Foro Económico Mundial y el Fondo de Aire Limpio, publicó una guía práctica sobre cómo las empresas pueden cuantificar las emisiones de contaminantes del aire a lo largo de sus cadenas … Read the full press release
Posted in Business, Energy, Gas & Oil, Environment, Industrial, Management, Switzerland
Tagged Andreas Ahrens, Claire Lund, Coalición para el Clima y el Aire Limpio, conferencia sobre el cambio climático, contaminación del aire, COP26, EY, Fondo de Aire Limpio, Foro Económico Mundial, GlaxoSmithKline, Grupo GEA, Grupo Inter IKEA, GSK, Haleon, huella de contaminación del aire, Instituto Ambiental de Estocolmo, La Alianza para el Aire Limpio, Moderna, Oracle, Pim Valdre, Sostenibilidad
Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022 vom CSO zu einem GSK Non-Executive Director mit zusätzlichen Verantwortlichkeiten zur Unterstützung von Forschung und Entwicklung (PRESSEMITTEILUNG) LONDON, 19-Jan-2022 — … Read the full press release
Posted in Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, biotechnologie, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Ernennung, F&E, Forschung und Entwicklung, Genome Research, Genomik, GlaxoSmithKline plc, GSK, Immunologie, Imperial College, Infektionskrankheiten, Jemperli, künstliche Intelligenz, maschinelles Lernen, Medikamente, Nucala, Onkologie, Pfizer, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D (PRESS RELEASE) LONDON, 19-Jan-2022 — /EuropaWire/ — GlaxoSmithKline … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, appointment, artificial-intelligence, biotechnology, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Genome Research, genomics, GlaxoSmithKline plc, GSK, immunology, Imperial College, infectious disease, Jemperli, Machine Learning, medicines, Nucala®, oncology, Pfizer, R&D, research and development, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. This … Read the full press release
Posted in Education, Healthcare, Internet & Online, News, Pharma & Biotech, Science, Technology
Tagged 6th annual EU Patients as Partners, AbbVie, Biotech, clinical development, clinical research, clinical trial, clinical trials, Conference, Conference Forum, data, dct, decentralized, DNA, EMD Serono, Gilead Sciences, GSK, INNOVATION, Ipsen, Janssen, Johnson & Johnson, Medicines Development, Merck KGaA, Michaela Dinboeck, MS trial, Noema Pharma, Novartis, Parkinsons disease, patient engagement, patient input, Patient Voice, patients, Patients as Partners Europe, Pfizer, pharma, Pharmaceutical, Pierre Fabre, Regeneron, Takeda, UCB
Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients. Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years. Researchers … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Society, Switzerland, United Kingdom
Tagged Africa, African genetic diversity, Chagas disease, drug therapeutics, genetic diversity, Genomic, GSK, Human genetics, Leprosy, Lutz Hegemann M.D., malaria, Novartis, Pauline Williams, Prof. Glenda Gray, Project Africa GRADIENT, SAMR, scientific research, sickle cell disease, South African Medical Research Council, therapeutics, tuberculosis
Agreement signed today supports scale-up of manufacturing capabilities in several European countries Vaccine candidate uses Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system (PRESS RELEASE) PARIS, 18-Sep-2020 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused … Read the full press release
Posted in Belgium, European Union, France, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Advanced purchase agreement, COVID-19, COVID-19 vaccine, EC, European Commission, GSK, influenza vaccine, Sanofi, vaccine
Brentford, United Kingdom, 14-Aug-2018 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Iain Mackay has been appointed GSK’s next Chief Financial Officer (CFO). He has also been appointed as an Executive Director to the GSK Board. Mr Mackay will … Read the full press release
Posted in Healthcare, Management, Pharma & Biotech, United Kingdom
Tagged appointment, CFO, Emma Walmsley, GSK, Healthcare, Iain Mackay, leadership, Management, pharma, Philip Hampton, Simon Dingemans
Critical role appointed as part of ongoing activities to strengthen and accelerate the Pharmaceuticals pipeline LONDON, 20-Apr-2018 — /EuropaWire/ — GlaxoSmithKline plc (GSK) today announced the appointment of Kevin Sin as Senior Vice President and Head of Worldwide Business Development for … Read the full press release
Posted in Business, Pharma & Biotech, United Kingdom
Tagged appointment, Dr. Hal Barron, GSK, HR, Kevin Sin, leadership, Management, pharmaceuticals
LONDON, 22-Mar-2018 — /EuropaWire/ — GSK today announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE). Belimumab and rituximab have different but potentially complementary mechanisms of action. … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged belimumab, Gijs van den Brink, GSK, lupus, rituximab, SLE, systemic lupus erythematosus
Regulatory milestone affirms GSK’s strong commitment and scientific capabilities to fighting infectious diseases LONDON/GENEVA, 29-Nov-2017 — /EuropaWire/ — GSK and Medicines for Malaria Venture (MMV) today announced the submission of a new drug application (NDA) by GSK to the United States … Read the full press release
LONDON, 29-Nov-2017 — /EuropaWire/ — Responding to the launch of the Industrial Strategy White Paper, published today by the UK Government, Phil Thomson, President, Global Affairs, at GSK said: “A new, long-term industrial strategy for the country is important and welcome. We … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, United Kingdom
Tagged GSK, Phil Thomson, UK Government's Industrial Strategy
The ATLAS-2M study will evaluate injections every two months in virally suppressed patients LONDON, 29-Nov-2017 — /EuropaWire/ — Today (27 November 2017) ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged ATLAS-2M study, cabotegravir, GSK, HIV-1 infection, John C Pottage Jr MD, rilpivirine, ViiV Healthcare
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
